FDA Approves New Long-Acting Insulin: Tresiba and Ryzodeg

On September 25, 2015, the FDA has approved Tresiba (insulin degludec SC injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart SC injection) as one of the treatment options to improve glycemic controls in adults with diabetes mellitus.

Read more

Posted in Drugs